Movability of advanced third-stage larva of Gnathostoma spinigerum exposed to albendazole sulphoxide in vitro.
| dc.contributor.author | Sukontason, K | en_US |
| dc.contributor.author | Klaolaor, P | en_US |
| dc.contributor.author | Sukontason, K | en_US |
| dc.contributor.author | Morakote, N | en_US |
| dc.contributor.author | Muangyimpong, Y | en_US |
| dc.contributor.author | Chaithong, U | en_US |
| dc.date.accessioned | 2009-05-27T15:09:22Z | |
| dc.date.available | 2009-05-27T15:09:22Z | |
| dc.date.issued | 1999-06-25 | en_US |
| dc.description | The Southeast Asian Journal of Tropical Medicine and Public Health. | en_US |
| dc.description.abstract | Movability of advanced third-stage larvae of Gnathostoma spinigerum exposed to albendazole sulphoxide (AlbSO), the active metabolite of albendazole, was determined in vitro. Larvae in control groups moved actively with the whole body for all 21 days of the study period. In larvae treated with AlbSO 1 microg/ml, the movement was significantly reduced after 11 days exposed to the drug and to be only a part of body on the 15th-21st days. In larvae treated with AlbSO 2 microg/ml, the movement was initiated in decreasing after 9th days and to be only a part of body on the 12th-17th days. Finally, worms were immobile but not dead on the 20th-21st days. Although there was no larvae died at 21st days exposed to AlbSO in both concentrations; but all worms were sluggish and may die later. These lethargic worms may not be able to migrate in patients and leading to cure. Albendazole may not be benefit for acute symptom clearance; however, it can prevent the recurrent migratory swelling after the treatment of 21 day-course. | en_US |
| dc.description.affiliation | Department of Parasitology, Faculty of Medicine, Chiang Mai University, Thailand. ksukonta@sd01.med.cmu.ac.th | en_US |
| dc.identifier.citation | Sukontason K, Klaolaor P, Sukontason K, Morakote N, Muangyimpong Y, Chaithong U. Movability of advanced third-stage larva of Gnathostoma spinigerum exposed to albendazole sulphoxide in vitro. The Southeast Asian Journal of Tropical Medicine and Public Health. 1999 Jun; 30(2): 379-81 | en_US |
| dc.identifier.uri | https://imsear.searo.who.int/handle/123456789/32058 | |
| dc.language.iso | eng | en_US |
| dc.source.uri | https://www.tm.mahidol.ac.th/seameo/1999-30-2/1999-30-2-379.pdf | en_US |
| dc.subject.mesh | Albendazole --pharmacology | en_US |
| dc.subject.mesh | Animals | en_US |
| dc.subject.mesh | Anthelmintics --pharmacology | en_US |
| dc.subject.mesh | Gnathostoma --drug effects | en_US |
| dc.subject.mesh | Humans | en_US |
| dc.subject.mesh | Larva --drug effects | en_US |
| dc.subject.mesh | Movement --drug effects | en_US |
| dc.subject.mesh | Spirurida Infections --drug therapy | en_US |
| dc.title | Movability of advanced third-stage larva of Gnathostoma spinigerum exposed to albendazole sulphoxide in vitro. | en_US |
| dc.type | In Vitro | en_US |
| dc.type | Journal Article | en_US |
| dc.type | Research Support, Non-U.S. Gov't | en_US |